WA MTP Sector Spotlight Series

The MTPConnect WA Life Sciences Innovation Hub invites you to join the monthly WA MTP Sector Spotlight Series event.

About this event

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast each month at the Harry Perkins Institute of Medical Research.

Details

Wednesday 9 November 2022

Fireside chat 8:00-9:00am AWST

Ground Floor Auditorium at Harry Perkins Institute of Medical Research, 6 Verdun Street Nedlands.

Agenda

7:30am Informal networking (COVID restrictions permitting) at ground floor of the Perkins Institute

8:00am Guided fireside chat

9:00am Event close

Featuring Recce Pharmaceuticals

Recce Pharmaceuticals (ASX: RCE) is an ASX listed pharmaceuticals company pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is comprised of broad-spectrum synthetic antibiotics, RECCE® 327 and RECCE® 435, and a synthetic anti-viral, RECCE® 529. Recce’s compounds, respectively, contain unique mechanisms of action against hypermutation on bacteria and viruses.

Join Recce’s CEO James Graham and CSO Michele Dilizia alongside MTPConnect’s Dr Tracey Wilkinson to discuss the development and commercialisation of anti-infectives, the regulatory pathway for antibiotics and the future of antimicrobial resistance.

About our speakers

James Graham

Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. Mr Graham was former Executive Director and has extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential. Mr Graham has served on Recce’s Board of Directors for six years with a focus on expanding Recce’s commercial opportunities and clinical initiatives.

Michele Dilizia

Ms Dilizia is the Chief Scientific Officer of Recce Pharmaceuticals and is a qualified Medical Scientist with a specialisation in medical microbiology. Ms Dilizia successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).

For any questions, please contact Rebekah Craggs and [email protected]